GS
BIIB icon

GTS Securities’s Biogen BIIB Stock Holding History

GTS Securities’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,381
Closed -$253K – 1383
2026
Q1 		$253K Buy
1,381
+236
+21% +$43.5K 0.01% 1208
2025
Q4 		$202K Sell
1,145
-2,195
-66% -$359K 0.01% 1284
2025
Q3 		$468K Buy
+3,340
New +$451K 0.02% 772
2024
Q4 		– Sell
-13,294
Closed -$2.58M – 1562
2024
Q3 		$2.58M Sell
13,294
-624
-4% -$131K 0.01% 1384
2024
Q2 		$3.23M Buy
+13,918
New +$3.02M 0.01% 1149
2024
Q1 		– Sell
-15,981
Closed -$3.74M – 3866
2023
Q4 		$4.14M Buy
15,981
+658
+4% +$162K 0.01% 1138
2023
Q3 		$3.94M Buy
15,323
+4,235
+38% +$1.13M 0.01% 1068
2023
Q2 		$3.16M Buy
+11,088
New +$3.3M 0.1% 181

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GTS Securities's BIIB Position: Q2 2026 in Review

GTS Securities sold out of Biogen (BIIB) in Q2 2026, closing a stake of 1,381 shares — an estimated $253K sold.

GTS Securities first reported a position in BIIB in Q2 2023 and held it in 8 quarters. The position peaked at $4.14M in Q4 2023. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • GTS Securities reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 1,381 Biogen shares in Q2 2026, an estimated $253K.
  • GTS Securities first reported a position in Biogen in Q2 2023 and held it in 8 quarters.
  • GTS Securities's Biogen position peaked at $4.14M in Q4 2023.
  • 1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.